New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 12, Issue 6, 2005, Pages 542-547

  O'Callaghan, Patrick A ^a,b   Fitzgerald, Anthony ^b   Fogarty, Jane ^b   Gaffney, Peter ^b   Hanbidge, Moira ^b   Boran, Gerald ^b   Enright, Helen ^b   Murphy, Jane ^b   McCarthy, Brendan ^b   Graham, Ian M ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Epidemiology; Risk factors; Smoking

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 12; C REACTIVE PROTEIN; CYSTEINE; HOMOCYSTEINE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE PREDISPOSITION; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; INCIDENCE; METABOLISM; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; RISK; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; CYSTEINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTEINE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; VON WILLEBRAND FACTOR;

EID: 33644878800     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/00149831-200512000-00005     Document Type: Article

References (36)

1. Ridker PM, Libby P. Nontraditional coronary risk factors and vascular biology: The frontiers of preventive cardiology. J Investig Med 1998; 46:338-350.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
3. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinaemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-1155.
4. Stampfer M, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-881.
5. Graham I, Daly L, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277:1775-1786.
6. Folsom A. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86:366-373.
7. Ridker P, Stampfer M, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-Reactive Protein, Fibrinogen, Homocysteine, Lipoprotein (a), and standard Cholesterol Screening as Predictors of Peripheral Arterial Disease. JAMA 2001; 285:2481-2485.
8. Hoffmeister A, Rothenbacher D, Bazner U, et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001; 87:262-266.
9. Meade T, Cooper J, Stirling Y, Howarth D. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88:610-617.
10. Ridker PM, Rifai N, Rose L, Buring J, Cook N. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
11. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
12. Schumacher A, Seljeflot I, Sommervoll L. Increased levels of markers of vascular inflammation in patients with coronary heart disease. Scand J Clin Lab Invest 2002; 62:59-68.
13. Levinson S, Elin R. What is C-reactive protein telling us about coronary artery disease? Arch Intern Med 2002; 162:389-392.
14. Ridker P, Cushman M, Stampfer M. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
15. Ridker P, Buring J, Shih H, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-733.
16. Tracey R, Lemaitre R, Psaty B. Relationship of C reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17:1121-1127.
17. Kuller L, Tracey R, Shaten J. Relation of C-reactive protein and coronary heart disease in the MIRFIT nested case control study. Multiple risk factor intervention Trial. Am J Epidemiol 1996; 144:537-547.
18. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological trials. J Cardiovasc Risk 1998; 5:229-232.
19. Brattstrom L, Wilcken D. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72:315-323.
20. Ueland P, Refsum H, Beresford S, Vollest S. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72:324-332.
21. El-Khairy L, Ueland P, Nygard O, Refsum H, Vollest S. Lifestyle and cardiovascular determinants of total cysteine in plasma: The Hordaland Homocysteine Study. Am J Clin Nutr 1999; 70:1016-1024.
22. El-Khairy L, Ueland P, Refsum H, Graham I, Vollest S. Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 2001; 103:2544-2549.
23. Goto S. Role of von Willebrand Factor for the onset of arterial thrombosis. Clin Lab 2001; 47:327-334.
24. Ruggeri Z. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14:257-279.
25. Gaede P, Vedel P, Parving H, Pedersen O. Elevated levels of plasma von Willebrand factor and the risk of macro and microvascular disease in type 2 diabetic patients with microalbuminuria. Nephrol Dial Transplant 2001; 16:2028-2033.
26. Zito F, Drummond F, Bujac S, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ. Epidemiological and genetic associations of activated factor XII concentration with Factor VII activity, fibrinopeptide A concentration and risk of coronary heart disease in men. Circulation 2000; 102:2058-2062.
27. Miller G, Esnouf P, Burgess A, Cooper J, Mitchell J. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997;17:2103-2106.
28. O'Callaghan P, Meleady R, Fitzgerald T, Graham I. Smoking and plasma homocysteine. Eur Heart J 2002; 23:1580-1586.
29. The EUROASPIRE II Investigators. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22:554-572.
30. Rasmussen K, Moller J. Total homocysteine in clinical practice. Ann Clin Biochem 2000; 37:627-648.
31. Albert M, Danielson E, Rifai N, Ridker P. Effect of statin therapy on C-reactive protein levels. JAMA 2001; 286:64-74.
32. Luftjohann D, Sigit J, Locatelli S, von Bergman K. High dose simvastatin decreases plasma concentrations of total homocysteine in patients with hypercholesterolaemia. Atherosclerosis 2000; 155:265-266.
33. Rumley A, Lowe G, Sweetnam P. von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart study. Br J Haematol 1999; 105:110-116.
34. Kohler H, Carter A, Stickland M, Grant P. Levels of activated factor XII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79:14-18.
35. Musial J, Undas A, Undas R, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost 2001; 85:221-225.
36. Rosenson R, Tangney C, Schaefer E. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001; 155:463-466.